Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
24 11 2020
Historique:
received: 04 06 2020
accepted: 28 09 2020
entrez: 13 11 2020
pubmed: 14 11 2020
medline: 15 5 2021
Statut: ppublish

Résumé

Multiple myeloma (MM) is a hematologic malignancy produced by a clonal expansion of plasma cells and characterized by abnormal production and secretion of monoclonal antibodies. This pathology exhibits an enormous heterogeneity resulting not only from genetic alterations but also from several epigenetic dysregulations. Here we provide evidence that Che-1/AATF (Che-1), an interactor of RNA polymerase II, promotes MM proliferation by affecting chromatin structure and sustaining global gene expression. We found that Che-1 depletion leads to a reduction of "active chromatin" by inducing a global decrease of histone acetylation. In this context, Che-1 directly interacts with histones and displaces histone deacetylase class I members from them. Strikingly, transgenic mice expressing human Che-1 in plasma cells develop MM with clinical features resembling those observed in the human disease. Finally, Che-1 downregulation decreases BRD4 chromatin accumulation to further sensitize MM cells to bromodomain and external domain inhibitors. These findings identify Che-1 as a promising target for MM therapy, alone or in combination with bromodomain and external domain inhibitors.

Identifiants

pubmed: 33186461
pii: S2473-9529(20)31958-3
doi: 10.1182/bloodadvances.2020002566
pmc: PMC7686885
doi:

Substances chimiques

Chromatin 0
Nuclear Proteins 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5616-5630

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Cell. 2012 Sep 28;151(1):68-79
pubmed: 23021216
Cancer Cell. 2016 Apr 11;29(4):464-476
pubmed: 27070701
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Oncogene. 2018 Mar;37(11):1503-1518
pubmed: 29321668
Am Soc Clin Oncol Educ Book. 2013;:
pubmed: 23714530
Front Genet. 2015 Apr 10;6:141
pubmed: 25914721
J Exp Clin Cancer Res. 2017 Feb 18;36(1):32
pubmed: 28214471
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Nat Rev Genet. 2016 May;17(5):284-99
pubmed: 26972587
Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Front Immunol. 2019 May 21;10:1121
pubmed: 31231360
Nucleic Acids Res. 2009 Jan;37(Database issue):D712-9
pubmed: 18981050
Onco Targets Ther. 2016 Sep 28;9:5943-5953
pubmed: 27729803
EMBO Rep. 2018 Mar;19(3):
pubmed: 29367285
PLoS One. 2017 Dec 12;12(12):e0189193
pubmed: 29232376
Genes Dev. 2015 Feb 1;29(3):238-49
pubmed: 25644600
Nat Commun. 2019 Oct 24;10(1):4843
pubmed: 31649247
Oncogene. 2017 Aug;36(31):4481-4497
pubmed: 28368411
F1000 Biol Rep. 2009;1:98
pubmed: 20495683
Leukemia. 2018 Oct;32(10):2224-2239
pubmed: 29581547
J Clin Invest. 2012 Oct;122(10):3456-63
pubmed: 23023717
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
FEBS Lett. 1996 Apr 8;384(1):48-52
pubmed: 8797801
Nat Rev Genet. 2016 Aug;17(8):487-500
pubmed: 27346641
Biochem J. 2013 Mar 1;450(2):311-20
pubmed: 23167988
Cell Stem Cell. 2013 Oct 3;13(4):446-58
pubmed: 24094325
Blood. 2018 May 10;131(19):2138-2150
pubmed: 29519805
Cancer Cell. 2008 Feb;13(2):167-80
pubmed: 18242516
Semin Cancer Biol. 2018 Aug;51:101-115
pubmed: 28962927
Genes Dev. 2006 Nov 1;20(21):2922-36
pubmed: 17079683
Cell. 2012 Sep 28;151(1):56-67
pubmed: 23021215
Nature. 2009 Aug 13;460(7257):863-8
pubmed: 19587682
Hepatology. 2019 Apr;69(4):1520-1534
pubmed: 30394550
Kidney Int. 2019 Apr;95(4):846-858
pubmed: 30770218
Cancer Cell. 2002 Nov;2(5):387-99
pubmed: 12450794
Leuk Res. 2018 Sep;72:52-58
pubmed: 30098518
Trends Biochem Sci. 2015 Aug;40(8):468-79
pubmed: 26145250
Nat Methods. 2015 Oct;12(10):963-965
pubmed: 26280331
FEBS Open Bio. 2018 Sep 04;8(10):1615-1623
pubmed: 30338213
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Mol Cell. 2011 Nov 18;44(4):609-20
pubmed: 22099308
Leuk Lymphoma. 2016 Nov;57(11):2526-34
pubmed: 27243588
Mol Cell. 2015 Feb 5;57(3):559-71
pubmed: 25578876
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
J Biol Chem. 2003 Sep 19;278(38):36496-504
pubmed: 12847090
PLoS Genet. 2014 Sep 04;10(9):e1004566
pubmed: 25188243
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Cancer Res. 2008 Dec 1;68(23):9654-62
pubmed: 19047142
Curr Opin Hematol. 2017 Jul;24(4):336-344
pubmed: 28441149
Cell. 2012 Oct 26;151(3):476-82
pubmed: 23101621
Leukemia. 2006 Jul;20(7):1288-90
pubmed: 16688228
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113
pubmed: 27531699
EMBO J. 2015 May 5;34(9):1214-30
pubmed: 25770584
Nat Rev Drug Discov. 2014 May;13(5):337-56
pubmed: 24751816

Auteurs

Tiziana Bruno (T)

SAFU Laboratory.

Francesca De Nicola (F)

SAFU Laboratory.

Giacomo Corleone (G)

SAFU Laboratory.

Valeria Catena (V)

SAFU Laboratory.

Frauke Goeman (F)

SAFU Laboratory.

Matteo Pallocca (M)

SAFU Laboratory.

Cristina Sorino (C)

SAFU Laboratory.

Gianluca Bossi (G)

Oncogenomic and Epigenetic Unit, and.

Bruno Amadio (B)

SAFU Laboratory.

Giovanni Cigliana (G)

Clinical Pathology Unit, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Maria Rosaria Ricciardi (MR)

Hematology, Department of Clinical and Molecular Medicine, "Sant'Andrea" Hospital-Sapienza, University of Rome, Rome, Italy.

Maria Teresa Petrucci (MT)

Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.

Alfonso Baldi (A)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Campania University "Luigi Vanvitelli," Caserta, Italy.

Mario Cioce (M)

Oncogenomic and Epigenetic Unit, and.

Giancarlo Cortese (G)

SAFU Laboratory.

Elisabetta Mattei (E)

CNR-Institute of Cell Biology and Neurobiology, IRCCS Fondazione Santa Lucia, Rome, Italy.

Roberta Merola (R)

Clinical Pathology Unit, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Umberto Gianelli (U)

Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca' Granda-Maggiore Policlinico, Hospital Foundation, Milan, Italy.

Luca Baldini (L)

Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca' Granda-Maggiore Policlinico, Hospital Foundation, Milan, Italy.

Francesco Pisani (F)

Hematology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Svitlana Gumenyuk (S)

Hematology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Andrea Mengarelli (A)

Hematology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Katja Höpker (K)

Department II of Internal Medicine, University Hospital of Cologne, Cologne, Germany.

Thomas Benzing (T)

Department II of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), and.
Systems Biology of Aging, University of Cologne, Cologne, Germany.

Bruno Vincenzi (B)

Campus Biomedico University, Rome, Italy; and.

Aristide Floridi (A)

SAFU Laboratory.

Claudio Passananti (C)

CNR-Institute of Molecular Biology and Pathology, Department of Molecular Medicine, Sapienza University, Rome, Italy.

Giovanni Blandino (G)

Oncogenomic and Epigenetic Unit, and.

Simona Iezzi (S)

SAFU Laboratory.

Maurizio Fanciulli (M)

SAFU Laboratory.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH